Chemotherapeutic Options for Colorectal Cancer Patients with Cardiovascular Diseases.

Author(s): Brunella Di Biasi, Tiziana Prochilo, Tony Sabatini, Alberto Zaniboni

Journal Name: Reviews on Recent Clinical Trials

Volume 8 , Issue 2 , 2013

Become EABM
Become Reviewer
Call for Editor


The high incidence of cardiovascular disease and colorectal cancer in the world's population means that these two conditions may coexist in the same patient. In addition fluoropyrimidines, backbone for the treatment of colorectal cancer in both early stage and advanced disease, have a well-characterized cardio-toxicity, which limits their use in patients with heart disease and limits their reintroduction in those patients who have shown this toxicity. For the treatment of this, increasing proportion of patients is now possible to consider fluoropyrimidines-free chemotherapy regimens that are examined in this work, with the attempt to provide a possible treatment algorithm for various situations encountered in clinical practice.

Keywords: Cardiovascular disease, cardiotoxicity, colorectal cancer, fluoropirymidines.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 07 October, 2013
Page: [128 - 135]
Pages: 8
DOI: 10.2174/15748871113089990046
Price: $65

Article Metrics

PDF: 24